Camp4 Therapeutics CAMP Insider Ownership

Updated Oct 10, 2026

Over the past year, CAMP insiders bought $77,433 of stock (32.93K shares) and sold $2.5 million (593.61K shares) on the open market.

• Camp4 Therapeutics' open-market purchases in the past 12 months came from 3 insiders, and its sales from 2 insiders.
• Among CAMP's insiders, Kelly Gold (Chief Financial Officer) was the top open-market buyer in the past 12 months, with $39,600 of stock purchased (10K shares) and the latest purchase on August 31, 2026.
• Meanwhile, the largest open-market sales of CAMP in the past 12 months were by Andrew J. Schwab (Director), totaling $2.5 million (591.88K shares), most recently on August 27, 2026.
• Per Business Quant, CAMP insiders together hold 14.3Mn shares based on their latest Form 4 filings, down 3.66% from 14.85Mn shares at the end of Q2 2026 and down 3.66% from 14.85Mn shares at the end of Q3 2025.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 95.32% (13.63Mn shares) of Camp4 Therapeutics' insider total, with the other 4.68% (669.38K shares) held directly.
• Per Business Quant, 11 insiders of CAMP hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• CAMP's three largest insider shareholders, per their latest Form 4 filings, are Andrew J. Schwab (Director, 4.97Mn shares), Enavate Sciences GP, LLC (10% owner, 3.79Mn shares) and Northpond Ventures II GP, LLC (10% owner, 2.24Mn shares).
• The holding of Andrew J. Schwab makes up 34.78% of all shares held by Camp4 Therapeutics insiders.
• Institutional investors held 71.95% of Camp4 Therapeutics stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 24.69%; other investors, including the public, hold roughly 3.36%.
• Over the trailing 12 months, 12 insiders reported transactions in CAMP stock across 26 Form 4 filings.
• Insider figures for CAMP include Form 4 filings through September 2, 2026.